PharmaNutra
€70.20Change from previous close: −1.40%Absolute change: −€1.00
At a glance
- Revenue growth
- +13.83%
- 2025 vs 2024
- Net income growth
- +20.44%
- 2025 vs 2024
- Net margin
- 15.0%
- 2024: 14.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 121 | 128 | 125 | 120 | 116 | — |
| Current assets | 69.4 | 74.7 | 72.9 | 68.1 | 64.0 | — |
| Cash and equivalents | 7.2 | 21.2 | 18.6 | 14.8 | 9.1 | — |
| Short-term investments | 7.9 | 7.8 | 12.0 | 7.2 | 6.6 | — |
| Inventory | 9.4 | 8.5 | 8.9 | 10.2 | 9.8 | — |
| Net property, plant and equipment | 24.3 | 24.1 | 24.1 | 24.3 | 24.8 | — |
| Goodwill | 17.6 | — | 17.6 | — | — | — |
| Other intangible assets | 7.2 | — | 6.9 | — | — | — |
| Long-term investments | 0.0 | — | 0.0 | — | — | — |
| Current liabilities | 33.9 | 31.4 | 31.0 | 31.1 | 31.0 | — |
| Accounts payable | 22.2 | 17.5 | 19.9 | 17.7 | 19.6 | — |
| Long-term debt | 12.3 | 13.3 | 14.4 | 14.9 | 15.8 | — |
| Total debt | 18.4 | 19.1 | 20.5 | 21.0 | 22.1 | — |
| Total liabilities | 51.4 | 53.7 | 54.0 | 53.7 | 54.4 | — |
| Total equity (incl. minority) | 69.5 | 74.5 | 71.2 | 66.1 | 61.2 | — |
| Retained earnings | 9.9 | 3.5 | 20.0 | 14.0 | 9.2 | — |
| Minority interest | -0.1 | -0.1 | -0.1 | -0.0 | 0.0 | — |